Xconomy |
Lilly Licenses Sigilon's Cell Encapsulation Tech for Diabetes Therapy
Xconomy A day after Pfizer decided to step back from the development of a universal cell therapy for cancer, Eli Lilly is jumping in, this time for diabetes. Lilly is licensing cell encapsulation technology from Cambridge, MA biotech Sigilon Therapeutics to ... Lilly, Sigilon Launch Up-to-$473M+ Type 1 Diabetes Partnership Eli Lilly ponies up $63M for Sigilon's diabetes cell therapies Lilly's next diabetes play would have patients implanted with engineered stem cells |
from diabetes - Google News
Social Plugin